Tumor-infiltrating lymphocytes for melanoma immunotherapy

Oliver Kepp; Peng Liu; Laurence Zitvogel; Guido Kroemer

doi:10.1080/2162402X.2023.2175506

Tumor-infiltrating lymphocytes for melanoma immunotherapy

Oliver Kepp, Peng Liu, Laurence Zitvogel, Guido Kroemer

Résultats de recherche: Contribution à un journal › Editorial

2 Citations (Scopus)

langue originale	Anglais
Numéro d'article	2175506
journal	OncoImmunology
Volume	12
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2023.2175506
état	Publié - 1 janv. 2023

Accès au document

10.1080/2162402X.2023.2175506

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{46dc7579bb09474db551b76a7b8b69d1,

title = "Tumor-infiltrating lymphocytes for melanoma immunotherapy",

author = "Oliver Kepp and Peng Liu and Laurence Zitvogel and Guido Kroemer",

note = "Funding Information: OK receives grants by the DIM ELICIT initiative of the Ile de France and Institut National du Cancer (INCa). GK is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universit{\'e} de Paris ANR-18-IDEX-0001. Funding Information: OK receives grants by the DIM ELICIT initiative of the Ile de France and Institut National du Cancer (INCa). GK is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR)–Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universit{\'e} de Paris ANR-18-IDEX-0001.",

year = "2023",

month = jan,

day = "1",

doi = "10.1080/2162402X.2023.2175506",

language = "English",

volume = "12",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Tumor-infiltrating lymphocytes for melanoma immunotherapy

AU - Kepp, Oliver

AU - Liu, Peng

AU - Zitvogel, Laurence

AU - Kroemer, Guido

N1 - Funding Information: OK receives grants by the DIM ELICIT initiative of the Ile de France and Institut National du Cancer (INCa). GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. Funding Information: OK receives grants by the DIM ELICIT initiative of the Ile de France and Institut National du Cancer (INCa). GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)–Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001.

PY - 2023/1/1

Y1 - 2023/1/1

UR - http://www.scopus.com/inward/record.url?scp=85147835124&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2023.2175506

DO - 10.1080/2162402X.2023.2175506

M3 - Editorial

C2 - 36776522

AN - SCOPUS:85147835124

SN - 2162-4011

VL - 12

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2175506

ER -